Header

UZH-Logo

Maintenance Infos

"Endothelial progenitor cells" as a therapeutic strategy in cardiovascular disease


Kränkel, Nicolle; Lüscher, Thomas F; Landmesser, Ulf (2012). "Endothelial progenitor cells" as a therapeutic strategy in cardiovascular disease. Current Vascular Pharmacology, 10(1):107-124.

Abstract

Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and mortality throughout middle- and high-income countries. More efficient preventive and regenerative therapeutic strategies are therefore urgently needed. The repeated finding that putative "endothelial progenitor cells" (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present review, we discuss the growing knowledge about various distinct cell populations which have been collectively termed "EPCs", including myeloid cells and progenitor cells of different origin. We also present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In addition, we will discuss recent insights into mechanisms leading to dysfunction of "EPCs" in cardiovascular disease. Those findings may help to optimize autologous cell-based treatment approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.

Abstract

Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and mortality throughout middle- and high-income countries. More efficient preventive and regenerative therapeutic strategies are therefore urgently needed. The repeated finding that putative "endothelial progenitor cells" (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present review, we discuss the growing knowledge about various distinct cell populations which have been collectively termed "EPCs", including myeloid cells and progenitor cells of different origin. We also present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In addition, we will discuss recent insights into mechanisms leading to dysfunction of "EPCs" in cardiovascular disease. Those findings may help to optimize autologous cell-based treatment approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.

Statistics

Citations

8 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

126 downloads since deposited on 14 Nov 2013
14 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Institute of Physiology
07 Faculty of Science > Institute of Physiology

04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:2012
Deposited On:14 Nov 2013 15:10
Last Modified:07 Dec 2017 17:55
Publisher:Bentham Science Publishers
ISSN:1570-1611
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.2174/157016112798829832
PubMed ID:22112352

Download

Download PDF  '"Endothelial progenitor cells" as a therapeutic strategy in cardiovascular disease'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 5MB
View at publisher